Advanced Tumors

Oncology
6
Pipeline Programs
6
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
3
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

HB
HaiHe BiopharmaChina - Shanghai
1 program
1
HH2710Phase 1/21 trial
Active Trials
NCT04198818TerminatedEst. Mar 2023
ModeX Therapeutics
1 program
1
MDX2004Phase 1/2
Opko Health
Opko HealthMIAMI, FL
1 program
1
MDX2004Phase 1/21 trial
Active Trials
NCT07110584RecruitingEst. Jun 2031
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
1 program
1
CS23546Phase 11 trial
Active Trials
NCT06245122RecruitingEst. May 2027
H
HutchmedChina - Hong Kong
1 program
1
HMPL-A83 injectionPhase 11 trial
Active Trials
NCT05429008Completed40Est. Apr 2025
CT
1 program
1
TQB2916 injectionPhase 11 trial
Active Trials
NCT05213767UnknownEst. Jul 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Opko HealthMDX2004
HaiHe BiopharmaHH2710
Chipscreen BiosciencesCS23546
HutchmedHMPL-A83 injection
Chia Tai TianQing Pharmaceutical GroupTQB2916 injection

Clinical Trials (5)

Total enrollment: 40 patients across 5 trials

NCT07110584Opko HealthMDX2004

Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors

Start: Oct 2025Est. completion: Jun 2031
Phase 1/2Recruiting
NCT04198818HaiHe BiopharmaHH2710

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Start: Jan 2020Est. completion: Mar 2023
Phase 1/2Terminated
NCT06245122Chipscreen BiosciencesCS23546

A Study of CS23546 in Subjects With Advanced Tumors

Start: Mar 2024Est. completion: May 2027
Phase 1Recruiting
NCT05429008HutchmedHMPL-A83 injection

A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm

Start: Jul 2022Est. completion: Apr 202540 patients
Phase 1Completed
NCT05213767Chia Tai TianQing Pharmaceutical GroupTQB2916 injection

Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors

Start: Feb 2022Est. completion: Jul 2023
Phase 1Unknown

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 40 patients
6 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)